Summary
Global Markets Direct’s, ‘AbbVie Inc. - Product Pipeline Review - 2016’, provides an overview of the AbbVie Inc.’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by AbbVie Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of AbbVie Inc.
- The report provides overview of AbbVie Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses AbbVie Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features AbbVie Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate AbbVie Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for AbbVie Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding AbbVie Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
AbbVie Inc. Snapshot 6
AbbVie Inc. Overview 6
Key Information 6
Key Facts 6
AbbVie Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
AbbVie Inc. - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 20
AbbVie Inc. - Pipeline Products Glance 22
AbbVie Inc. - Late Stage Pipeline Products 22
AbbVie Inc. - Clinical Stage Pipeline Products 25
AbbVie Inc. - Early Stage Pipeline Products 27
AbbVie Inc. - Drug Profiles 30
adalimumab 30
daclizumab 33
elotuzumab 37
ibrutinib 39
venetoclax 46
Viekira-3QD 50
(ombitasvir + paritaprevir + ritonavir) + dasabuvir 51
atrasentan hydrochloride 52
elagolix sodium 54
fluvoxamine maleate 56
glecaprevir 57
glecaprevir + pibrentasvir 59
ombitasvir 61
paricalcitol 63
paritaprevir 64
pibrentasvir 66
upadacitinib tartrate 67
veliparib 68
depatuxizumab mafodotin 72
ABT-122 74
ABT-436 76
ABT-981 77
depatuxizumab 78
navitoclax dihydrochloride 79
ABBV-075 81
ABBV-084 82
ABBV-085 83
ABBV-221 84
ABBV-672 85
ABBV-838 86
ABBV-8E12 87
ABT-165 88
ABT-257 89
ABT-399 90
ABT-555 91
ABT-700 92
ABT-767 93
ABT-957 94
ilorasertib 95
A-1048400 97
A-1262543 98
A-1264087 99
A-431404 100
A-705253 101
A-889425 102
A-988315 103
ABT-207 104
ABT-737 105
APG-880 107
Biologics for Undisclosed Indication 108
h-5F9AM8 109
Monoclonal Antibodies to Inhibit RGMa for Multiple Sclerosis 110
Monoclonal Antibody Conjugates for Oncology 111
Small Molecule to Inhibit PKC Theta for Autoimmune Disease 112
Small Molecule to Inhibit WEE-1 for Oncology 113
Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Uterine Fibroids and Oncology 114
SOL-1 115
A-893 116
Monoclonal Antibodies for Chronic Pain 117
Small Molecules to Inhibit CDPK1 for Protozoal Infections 118
Small Molecules to Inhibit Jak1 for Undisclosed Indication 119
Small Molecules to Inhibit MCL-1 for Cancer 120
AbbVie Inc. - Pipeline Analysis 121
AbbVie Inc. - Pipeline Products by Target 121
AbbVie Inc. - Pipeline Products by Route of Administration 125
AbbVie Inc. - Pipeline Products by Molecule Type 126
AbbVie Inc. - Pipeline Products by Mechanism of Action 127
AbbVie Inc. - Recent Pipeline Updates 130
AbbVie Inc. - Dormant Projects 177
AbbVie Inc. - Discontinued Pipeline Products 182
Discontinued Pipeline Product Profiles 182
AbbVie Inc. - Company Statement 187
AbbVie Inc. - Locations And Subsidiaries 190
Head Office 190
Other Locations & Subsidiaries 190
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 198
Disclaimer 199
List of Tables
AbbVie Inc., Key Information 11
AbbVie Inc., Key Facts 11
AbbVie Inc. - Pipeline by Indication, 2016 13
AbbVie Inc. - Pipeline by Stage of Development, 2016 19
AbbVie Inc. - Monotherapy Products in Pipeline, 2016 20
AbbVie Inc. - Combination Treatment Modalities in Pipeline, 2016 21
AbbVie Inc. - Partnered Products in Pipeline, 2016 22
AbbVie Inc. - Partnered Products/ Combination Treatment Modalities, 2016 23
AbbVie Inc. - Out-Licensed Products in Pipeline, 2016 25
AbbVie Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2016 26
AbbVie Inc. - Pre-Registration, 2016 27
AbbVie Inc. - Filing rejected/Withdrawn, 2016 28
AbbVie Inc. - Phase III, 2016 29
AbbVie Inc. - Phase II, 2016 30
AbbVie Inc. - Phase I, 2016 31
AbbVie Inc. - Preclinical, 2016 32
AbbVie Inc. - Discovery, 2016 34
AbbVie Inc. - Pipeline by Target, 2016 126
AbbVie Inc. - Pipeline by Route of Administration, 2016 130
AbbVie Inc. - Pipeline by Molecule Type, 2016 131
AbbVie Inc. - Pipeline Products by Mechanism of Action, 2016 132
AbbVie Inc. - Recent Pipeline Updates, 2016 135
AbbVie Inc. - Dormant Developmental Projects,2016 182
AbbVie Inc. - Discontinued Pipeline Products, 2016 187
AbbVie Inc., Subsidiaries 195
List of Figures
AbbVie Inc. - Pipeline by Top 10 Indication, 2016 13
AbbVie Inc. - Pipeline by Stage of Development, 2016 19
AbbVie Inc. - Monotherapy Products in Pipeline, 2016 20
AbbVie Inc. - Partnered Products in Pipeline, 2016 22
AbbVie Inc. - Pipeline by Top 10 Target, 2016 126
AbbVie Inc. - Pipeline by Route of Administration, 2016 130
AbbVie Inc. - Pipeline by Molecule Type, 2016 131
AbbVie Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016 132
